Latest Regulatory Milestones News

Island Pharmaceuticals has completed its acquisition of the broad-spectrum antiviral Galidesivir and is progressing regulatory discussions with the FDA to fast-track approval using the Animal Rule, backed by compelling preclinical data.

CurveBeam AI reports a 33% rise in device purchase orders and secures a $6.5 million placement alongside a landmark China distribution partnership. The company advances FDA regulatory milestones and establishes a vendor financing facility to boost sales.

CurveBeam AI has inked a decade-long exclusive partnership with a major Chinese medical device joint venture, unlocking rapid market entry and a $10 million capital boost to expand its weight bearing CT and AI solutions across Greater China.

Agrimin Limited continues its strategic review of the Mackay Potash Project while initiating new geophysical surveys in Western Australia’s West Arunta region, alongside ongoing cost reductions and a stable cash position.

St Barbara Limited reports steady progress on its Simberi Expansion Project in Papua New Guinea and Atlantic Gold Projects in Canada, despite production challenges and pending regulatory decisions. A recent A$58 million capital raise strengthens its financial position for growth.

Ark Mines secured a $4.5 million strategic investment from QIC to fast-track its Sandy Mitchell Rare Earth Project, achieving key drilling and environmental milestones that pave the way for production by late 2027.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

Amplia Therapeutics reports encouraging interim results for narmafotinib in metastatic pancreatic cancer, alongside a successful capital raise and key patent allowance.

Siren Gold Limited has bolstered its leadership and financial position while delivering encouraging exploration results across its New Zealand gold and antimony projects, setting the stage for resource expansion and development progress.

Neurotech International has initiated an Authorised Prescriber program for its lead therapy NTI164, expanding access for children with neurodevelopmental disorders in Australia. The company also secured a Rare Pediatric Disease Designation from the US FDA for NTI164 in Rett Syndrome, marking a key regulatory milestone.

Diatreme Resources reported progress on its Northern Silica Project with key regulatory approvals and metallurgical successes, while agreeing to sell its Clermont Copper/Gold Project to Moonlight Resources, retaining a significant stake.

Optiscan Imaging Ltd secured $17.75 million in a fully underwritten equity raise, fueling clinical studies and regulatory preparations for its innovative medical imaging devices. The company also reported progress in international trials and strengthened its cash position to nearly $20 million.